Sensitivity, specificity, positive predictive value and negative predictive value of antibody isotypes when comparing patients with anti-CCP-negative RA versus non-RA patients (persistent non-RA and resolving)
| Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | |
|---|---|---|---|---|
| Anti-CCP | 0.0% (0.0% to 6.8%) | 98.2% (94.8% to 99.6%) | 0.0% (0.0% to 69.5%) | 75.6% (69.3% to 81.1%) |
| Rheum factor | ||||
| IgG | 20.8% (10.9% to 34.1%) | 92.2% (87.1% to 95.8%) | 45.8% (25.6% to 67.2%) | 78.6% (72.2% to 84.1%) |
| IgA | 13.2% (5.5% to 25.4%) | 91.0% (85.6% to 94.9%) | 31.8% (13.9% to 54.9%) | 76.8% (70.3% to 82.5%) |
| Anti-CitVimentin | ||||
| IgG | 22.6% ((12.3% to 36.2%) | 83.2% (76.7% to 88.6%) | 30.0% (16.6% to 46.5%) | 77.2% (70.4% to 83.2%) |
| IgA | 26.4% (15.3% to 40.3%) | 73.1% (65.6% to 79.6%) | 23.7% (13.6% to 36.6%) | 75.8% (68.4% to 82.2%) |
| Anti-CarVimentin | ||||
| IgG | 3.8% (0.6% to 13.0%) | 94.0% (89.3% to 97.1%) | 16.7% (2.6% to 48.4%) | 75.5% (69.1% to 81.2%) |
| IgA | 16.9% (8.1% to 29.8%) | 88.0% (82.1% to 92.5%) | 31.0% (15.3% to 50.8%) | 76.9% (70.3% to 82.7%) |
| Anti-AcVimentin | ||||
| IgG | 13.2% (5.5% to 25.4%) | 86.2% (80.1% to 91.1%) | 23.3% (9.9% to 42.3%) | 75.8% (69.1% to 81.7%) |
| IgA | 30.2% (18.4% to 44.3%) | 64.7% (56.9% to 71.9%) | 21.3% (12.7% to 32.3%) | 74.5% (66.6% to 81.4%) |
AcVim, acetylated vimentin peptide; CarVim, carbamylated vimentin peptide; CitVim, citrullinated vimentin peptide; NPV, negative predictive value; PPV, positive predictive value; RA, rheumatoid arthritis.